DNA aptamers in COVID-19 research

Show simple item record

dc.contributor.author Jain, Sanya
dc.contributor.author Singh, Somesh Pratap
dc.contributor.author Mayya, Chaithra
dc.contributor.author Majumdar, Sharmistha
dc.contributor.author Bhatia, Dhiraj
dc.date.accessioned 2020-10-21T05:35:28Z
dc.date.available 2020-10-21T05:35:28Z
dc.date.issued 2020-11
dc.identifier.citation Jain, Sanya; Singh, Somesh Pratap; Mayya, Chaithra; Majumdar, Sharmistha and Bhatia, Dhiraj, “DNA aptamers in COVID-19 research”, Current Science, vol. 119, no. 9, pp. 1489-1498, Nov. 2020. en_US
dc.identifier.issn 0011-3891
dc.identifier.uri https://wwwops.currentscience.ac.in/Volumes/119/09/1489.pdf
dc.identifier.uri https://repository.iitgn.ac.in/handle/123456789/5774
dc.description.abstract Novel Coronavirus (SARS-CoV-2) a variant of Severe Acute Respiratory Syndrome (SARS) family has claimed around 0.7 million lives and 20 million people worldwide have been infected. It has been declared a pandemic by the World Health Organization. COVID-19 is transmitted mainly through aerosol droplets from patients (both asymptomatic and symptomatic) to healthy people. Its high rate of transmission demands a quick and early diagnosis of patients followed by urgent quarantine of the affected ones. Since the SARS-CoV-2 virus is mutating, it's of utmost importance to develop a quick diagnosis against it. The current techniques use either PCR-based methods or antibody-based ELISA methods for diagnosis, which are both time-consuming and expensive. This is the biggest impediment in large scale diagnosis of COVID-19. Multiple biosensors based on antibodies and aptamers have been reported and tested. Aptamers seem much more lucrative due to ease of synthesis, cost effectiveness and extremely high degree of sensitivity in terms of detection, less immunogenicity and robustness to modifications. We present an elaborative history and characterization of aptamers, their selection strategies, and their applications to multiple viruses such as HIV, HCV and SARS-CoV. However, to date, no aptamers have been designed against any of the protein components or the genomic RNA of SARS-CoV-2. Based on the success of aptamers against many viruses, we argue for the future exploration of aptamers in the context of SARS-CoV-2 diagnostic testing.
dc.description.statementofresponsibility by Sanya Jaina, Somesh Pratap Singh, Chaithra Mayya, Sharmistha Majumdar and Dhiraj Bhatia
dc.language.iso en_US en_US
dc.publisher Indian Academy of Sciences en_US
dc.subject SARS-Cov2 en_US
dc.subject Coronavirus en_US
dc.subject DNA Aptamers en_US
dc.subject Coat Proteins en_US
dc.subject Biosensing en_US
dc.subject Diagnostics en_US
dc.subject Therapeutics en_US
dc.title DNA aptamers in COVID-19 research en_US
dc.type Article en_US
dc.relation.journal Current Science


Files in this item

Files Size Format View

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record

Search Digital Repository


Browse

My Account